[1]崔 迪.基于ARRGS的风险评分模型预测HCC患者的预后及GLMN基因在肿瘤组织表达验证[J].现代检验医学杂志,2025,40(04):35-42,49.[doi:10.3969/j.issn.1671-7414.2025.04.007]
　CUI Di.Prediction of the Prognosis of HCC Patients Based on ARRGS Risk Scoring Model and Validation of GLMN Gene Expression in Tumor Tissues[J].Journal of Modern Laboratory Medicine,2025,40(04):35-42,49.[doi:10.3969/j.issn.1671-7414.2025.04.007]
点击复制

基于ARRGS的风险评分模型预测HCC患者的预后及GLMN基因在肿瘤组织表达验证()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年04期
页码:
35-42,49
栏目:
论著
出版日期:
2025-07-15

文章信息/Info

Title:
Prediction of the Prognosis of HCC Patients Based on ARRGS Risk Scoring Model and Validation of GLMN Gene Expression in Tumor Tissues
文章编号:
1671-7414（2025）04-035-09
作者:
崔 迪
（阜阳师范大学阜阳医学院，安徽阜阳 236037）
Author(s):
CUI Di
（Fuyang Normal University, Fuyang Medical School, Anhui Fuyang 236037, China）
关键词:
肝细胞癌; 风险评分模型; 同种异体移植排斥相关基因; 血管球蛋白
分类号:
R735.7；R730.43
DOI:
10.3969/j.issn.1671-7414.2025.04.007
文献标志码:
A
摘要:
目的 评估基于同种异体移植排斥相关基因（ARRGS）的风险评分模型对肝细胞癌（HCC）患者的预后预测能力，并验证关键基因血管球蛋白（GLMN）在HCC 中的表达水平。方法 从癌症基因组图谱（The Cancer GenomeAtlas，TCGA）数据库下载HCC 表达数据，从Misgdb 数据库下载ARRGS 基因集，构建ARRGS 相关的分子亚型。采用Lasso-COX 回归分析建立预后模型，并通过Kaplan-Meier 生存分析、时间依赖性ROC 曲线及内部验证来评估模型的预测性能。收集2020 年1 月～ 2023 年12 月间，于阜阳民生医院接受根治性手术的12 对HCC 肿瘤和癌旁组织样本，利用免疫印迹试验（WB）、实时荧光定量PCR（RT-qPCR）和免疫组织化学（IHC）染色验证GLMN 在HCC 样本中的表达水平，并分析GLMN 与HCC 患者甲胎蛋白（AFP）水平的相关性。结果 基于ARRGS 构建了两个分子亚型，Cluster 1 表现出较差的预后和较高的免疫浸润水平。利用ARRGS 相关差异基因构建了以DYRK3，GLMN，MRPL3 和NME1 组成的预后模型，对患者1，3，5 年的预后具有较高的预测效能。临床样本中，WB，RT-qPCR 证实了GLMN的蛋白水平（t=4.275，P=0.023）和mRNA 水平（t=8.313，P=0.003）在肿瘤组织中升高，且与患者AFP 水平的升高密切相关（r=0.688，P=0.028）。结论 基于ARRGS 的风险评分模型，能够有效预测HCC 患者的预后，而GLMN 在HCC 肿瘤组织中表达升高，可能成为HCC 可靠的诊断标志物。
Abstract:
Objective To evaluate the prognostic predictive capability of a risk scoring model based on allograft rejectionrelated genes (ARRGS) in patients with hepatocellular carcinoma (HCC) and to validate the expression levels of the key gene Glomulin(GLMN) in HCC. Methods Expression data for HCC were downloaded from The Cancer Genome Atlas (TCGA) database, and ARRGS gene sets were obtained from the Misgdb database to construct ARRGS-related molecular subtypes. A prognostic model was developed using Lasso-Cox regression analysis, and its predictive performance was assessed through Kaplan-Meier survival analysis, time-dependent ROC curves, and internal validation. Twelve pairs of HCC tumor and adjacent non-tumor tissues were collected from patients who underwent radical surgery at Fuyang Minsheng Hospital between January 2020 and December 2023. The expression levels of GLMN in these samples were validated using Western blot(WB) , realtime quantitative PCR (RT-qPCR) and immunohisto chemistry(IHC). Additionally, the correlation between GLMN expression and alpha-fetoprotein (AFP) levels in HCC patients were analyzed. Results Two molecular subtypes were identified based on ARRGS, with Cluster 1 demonstrating poorer prognosis and higher levels of immune infiltration. A prognostic model was constructed using ARRGS-related differentially expressed genes, including DYRK3, GLMN, MRPL3 and NME1, which exhibited robust predictive performance for 1-, 3- and 5-year patient survival. In clinical samples, GLMN protein (t=4.275, P=0.023) and mRNA (t=8.313, P=0.003) levels were significantly elevated in tumor tissues, as confirmed by WB and RT-qPCR, and were strongly correlated with elevated AFP levels (r=0.688, P=0.028). Conclusion The ARRGS-based risk scoring model effectively predicts the prognosis of HCC patients. Elevated GLMN expression in HCC tumor tissues suggests its potential as a reliable diagnostic biomarker for HCC.

参考文献/References:

[1] GILLES H , GARBUTT T, LANDRUM J. Hepatocellular carcinoma[J]. Critical Care Nursing Clinics of North America，2022，34(3)：289-301.
[2] WANG Y, DENG B C. Hepatocellular carcinoma:molecular mechanism, targeted therapy, and biomarkers[J]. Cancer Metastasis Reviews, 2023,42(3): 629-652.
[3] LUO Y, TENG F, FU H, et al. Immunotherapy in liver transplantation for hepatocellular carcinoma: Pros and cons[J]. World Journal of Gastrointestinal Oncology,2022, 14(1): 163-180.
[4] MEHTA N, HEIMBACH J, HARNOIS D M, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant[J]. JAMA Oncology，2017，3(4)：493-500.
[5] LI S N, XIA H, WANG Z Y, et al. Intratumoral microbial heterogeneity affected tumor immune microenvironment and determined clinical outcome of HBV-related HCC[J]. Hepatology (Baltimore, Md.),2023, 78(4): 1079-1091.
[6] CHEN C, WANG Z H, DING Y, et al. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma[J]. Frontiers in Immunology,2023, 14: 1133308.
[7] LAI Q, IESARI S, FINKENSTEDT A, et al. Hepatocellular carcinoma recurrence after acute liver allograft rejection treatment: a multicenter European experience[J]. Hepatobiliary & Pancreatic Diseases International, 2019, 18(6): 517-524.
[8] SHI T, BURG A R, CALDWELL J T, et al. Singlecell transcriptomic analysis of renal allograft rejection reveals insights into intragraft TCR clonality[J]. the Journal of Clinical Investigation, 2023, 133(14):e170191.
[9] SHI T, ROSKIN K, BAKER B M, et al. Advanced genomics-based approaches for defining allograft rejection with single cell resolution[J]. Frontiers in Immunology, 2021, 12: 750754.
[10] LI Y, MO H Y, WU S L, et al. A novel lactate metabolism-related gene signature for predicting clinical outcome and tumor microenvironment in hepatocellular carcinoma[J]. Frontiers in Cell and Developmental Biology，2021，9：801959.
[11] JIANG X Y, YANG C, WANG Z Y, et al. Lossof-function variants in GLMN are associated with generalized skin hyperpigmentation with or without glomuvenous malformation[J]. the British Journal of Dermatology, 2024, 191(1): 107-116.
[12] 殷杰. 乳腺癌和BRBNS 致病基因的鉴定及功能分析[D]. 上海: 上海交通大学,2017. YIN J. Identifying and functional validation causative variants from breast cancer and blue rubber bleb nevus syndrome[D]. Shanghai: Shanghai JiaoTong University,2017.
[13] CAO Q Y, LI M. GLMN variants cause skin hyperpigmentation: a promising potential therapeutic target[J]. the British Journal of Dermatology，2024， 191(1):11.
[14] MCMAHON M H, TAHIR N, BALASUBRAMANIAN M. GLMN causing vascular malformations: the clinical and genetic differentiation of cutaneous venous malformations[J]. BMJ Case Reports, 2022, 15(6):e246114.
[15] DENG S Y, ZHANG Y B, WANG H B, et al. ITPRIPL1 binds CD3ε to impede T cell activation and enable tumor immune evasion[J]. Cell, 2024, 187(9): 2305-2323.e33.
[16] RAVI R, NOONAN K A, PHAM V, et al. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy[J]. Nature Communications,2018, 9(1): 741.
[17] JIANG P, GU S Q, PAN D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response[J]. Nature Medicine, 2018,24(10): 1550-1558.
[18] LI G Q, ZHANG D X, LIANG C W, et al. Construction and validation of a prognostic model of pyroptosis related genes in hepatocellular carcinoma[J]. Frontiers in Oncology, 2022, 12: 1021775.
[19] XU D F, WANG Y, ZHOU K L, et al. Development and validation of a novel 8 immune gene prognostic signature based on the immune expression profile for hepatocellular carcinoma[J]. OncoTargets and Therapy,2020, 13: 8125-8140.
[20] XU M J, LIU Y, WAN H L, et al. Overexpression of nucleotide metabolic enzyme DUT in hepatocellular carcinoma potentiates a therapeutic opportunity through targeting its dUTPase activity[J]. Cancer Letters， 2022，548：215898.
[21] WANG Y F, GAO S, CHEN L, et al. DUT enhances drug resistance to proteasome inhibitors via promoting mitochondrial function in multiple myeloma[J]. Carcinogenesis, 2022, 43(11): 1030-1038.
[22] ROMAGNOLO A P, ROMAGNOLO D F, SELMIN O I. BRCA1 as target for breast cancer prevention and therapy[J]. Anti-Cancer Agents in Medicinal Chemistry,2015, 15(1): 4-14.
[23] GUO Z Y, LIU Y, LING Q, et al. Pretransplant use of immune checkpoint inhibitors for hepatocellular carcinoma:a multicenter, retrospective cohort study[J]. American Journal of Transplantation, 2024, 24(10): 1837-1856.
[24] SCHNICKEL G T, FABBRI K, HOSSEINI M, et al. Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab[J]. American Journal of Transplantation， 2022，22(6):1699-1704.
[25] 孙飞, 黎春明. 基于免疫细胞组织浸润的免疫评分模型预测前列腺癌免疫治疗效果及预后分析研究[J]. 现代检验医学杂志,2023,38(3):189-194. SUN F, LI C M. Prediction of immunotherapy effect and prognosis of prostate cancer based on immune cell tissue infiltration immune score model[J]. Journal of Modern Laboratory Medicine, 2023, 38(3): 189-194.
[26] HUANG J Q, WU Q L, GELLER D A, et al. Macrophage metabolism, phenotype, function, and therapy in hepatocellular carcinoma (HCC)[J]. Journal of Translational Medicine, 2023, 21(1): 815.
[27] RUF B, BRUHNS M, BABAEI S, et al. Tumorassociated macrophages trigger MAIT cell dysfunction at the HCC invasive margin[J]. Cell, 2023, 186(17):3686-3705.e32.
[28] LEE Y H, YOON A R, YUN C O, et al. Dual-specificity kinase DYRK3 phosphorylates p62 at the Thr-269 residue and promotes melanoma progression[J]. the Journal of Biological Chemistry, 2024, 300(4): 107206.
[29] CHEN D W, NEMAZANYY I, PEULEN O, et al. Elp3-mediated codon-dependent translation promotes mTORC2 activation and regulates macrophage polarization[J]. the EMBO Journal, 2022, 41(18):e109353.
[30] YANG J, L? Z H, HUANG J T, et al. High expression of NME1 correlates with progression and poor prognosis in patients of hepatocellular carcinoma[J]. International Journal of Clinical and Experimental Pathology, 2017, 10(8): 8561-8568.

相似文献/References:

[1]邓旭,王晓亮.肝细胞癌患者血清趋化因子CXCR12和SA的表达及临床意义[J].现代检验医学杂志,2015,30(06):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
　DENG Xu,WANG Xiao-liang.Expression and Clinical Significance of Serum CXCR12 and SA in Patients with Hepatocarcinoma[J].Journal of Modern Laboratory Medicine,2015,30(04):49.[doi:10.3969/j.issn.1671-7414.2015.06.014]
[2]毛丽萍,何义民,韩 刚,等.血浆Dickkopf同源物1检测对肝细胞癌的诊断价值[J].现代检验医学杂志,2016,31(05):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
　MAO Li-ping,HE Yi-min,HAN Gang,et al.Diagnosis Value of Detecting Plasma Dickkopf-1 Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2016,31(04):62.[doi:10.3969/j.issn.1671-7414.2016.05.016]
[3]阮瑞杨,陈修荣,赵世元.抗EZH2自身抗体IgG在肝癌患者血清中的表达及意义[J].现代检验医学杂志,2017,32(02):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
　RUAN Rui-yang,CHEN Xiu-rong,ZHAO Shi-yuan.Expression and Significance of Anti EZH2 Autoantibodies IgG in Hepatocellular Carcinoma Patient's Serum Samples[J].Journal of Modern Laboratory Medicine,2017,32(04):72.[doi:10.3969/j.issn.1671-7414.2017.02.019]
[4]隆绍平,邓世群,赵世元.PTPN12蛋白表达下调与原发性肝细胞癌患者复发和预后关系研究[J].现代检验医学杂志,2018,33(01):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　LONG Shao-ping,DENG Shi-qun,ZHAO Shi-yuan.Association between Downregulation of PTPN12 Protein and Recurrence and Prognosis in Patients with Primary Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(04):86.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[5]毛丽萍,王跃国,王 健,等.CMIA法测定血清DCP与AFP对肝细胞癌的诊断价值[J].现代检验医学杂志,2018,33(06):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
　MAO Li-ping,WANG Yue-guo,WANG Jian,et al.Diagnostic Value of the Serum DCP and AFP Determined by CMIA in Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2018,33(04):38.[doi:10.3969/j.issn.1671-7414.2018.06.010]
[6]吴良银,李文丽,刘 俊.肝细胞癌患者生存预后相关长链非编码RNA(LncRNA)的生物信息学分析[J].现代检验医学杂志,2019,34(04):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
　WU Liang-yin,LI Wen-li,LIU Jun.Bioinformatics Analysis of Long-Chain Non-Coding RNA Related to Survival and Prognosis in Patients with Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2019,34(04):18.[doi:10.3969/j.issn.1671-7414.2019.04.005]
[7]吴良银,李文丽,刘　俊.基于GEO数据的病毒相关性肝癌潜在生物基因标志物的筛选及生物信息学分析[J].现代检验医学杂志,2021,36(06):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
　WU Liang-yin,LI Wen-li,LIU Jun.Screening and Bioinformatics Analysis of Potential Biomarkers for Virus-associated Hepatocellular Carcinoma Based on GEO Data[J].Journal of Modern Laboratory Medicine,2021,36(04):106.[doi:10.3969/j.issn.1671-7414.2021.06.022]
[8]陈 偲,李忠辉,王 颖.miR-198 通过靶向ZEB2 调控EMT 过程抑制肝癌细胞增殖和迁移的机制研究[J].现代检验医学杂志,2022,37(04):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
　CHEN Si,LI Zhong-hui,WANG Ying.Study on the Mechanism of miR-198 Inhibiting the Proliferation and Migration of Hepatoma Cells by Regulating EMT Process by Targeting ZEB2[J].Journal of Modern Laboratory Medicine,2022,37(04):23.[doi:10.3969/j.issn.1671-7414.2022.04.005]
[9]王 路,叶 莎,韩 霞,等.循环外泌体miRNA 检测对肝细胞癌临床诊断效能的Meta 分析[J].现代检验医学杂志,2022,37(04):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
　WANG Lu,YE Sha,HAN Xia,et al.Meta-Analysis of the Diagnostic Value of Circulating Exosomes miRNA Detection for Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2022,37(04):59.[doi:10.3969/j.issn.1671-7414.2021.04.012]
[10]时晓晓,董 翔,于若卉,等.miR-203a-3p 靶向GLS1 调控HCC 细胞增殖、迁移、侵袭的机制研究[J].现代检验医学杂志,2022,37(05):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]
　SHI Xiao-xiao,DONG Xiang,YU Ruo-hui,et al.Mechanism of miR-203a-3p Targeting GLS1 to Regulate the Proliferation, Migration and Invasion of HCC Cells[J].Journal of Modern Laboratory Medicine,2022,37(04):86.[doi:10.3969/j.issn.1671-7414.2022.05.018]

备注/Memo

备注/Memo:
作者简介：崔迪（1990-），男，硕士，主管检验师，助教，主要研究方向：肿瘤分子生物学，E-mail：349768352@qq.com。
更新日期/Last Update: 2025-07-15